Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 -17 years, broadening the population in which nipocalimab has been studied Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRapositive adolescents (aged 12 – 17 years) living with […]

Canadians Show Strong Loyalty and Satisfaction to Financial Advisors, But Younger Investors Less Certain: Vanguard Study

A new Vanguard Canada “Value of Advice” survey reveals that while financial advisors in Canada enjoy high levels of client satisfaction and loyalty, younger investors are increasingly opting to manage their assets through online brokerages. Among Canadian investors, 44% feel their advisor provides high value, and 74% believe their financial advisor is worth every dollar

AdvilĀ® Tackles Pain as the Official Pain Relief Partner of NFL Canada

The new campaign features Canadian NFL Player Chase Brown of the Cincinnati Bengals Today, Advil proudly announced it is the official pain relief partner of the NFL in Canada. Recognizing that tough pain can slow anyone down, this partnership highlights the fast-acting relief of Advil alongside the excitement of the NFL. The campaign features Chase

BTB REIT Announces its Distribution for the Month of October 2024

BTB Real Estate Investment Trust (TSX: BTB.UN) (“BTB” or the “REIT”) announced today that the monthly cash distribution for the month of October 2024 is $0.025 per unit, representing $0.30 per unit on an annualized basis. The cash distribution will be paid on November 15th, 2024, to unitholders of record on October 31st, 2024. AboutBTB

HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi

NAPLES, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a leader in connecting patients, doctors, and healthcare data, announced the filing of its non-provisional patent this past week with the United States Patent and Trademark Office (USPTO) for ARi, an innovative artificial intelligence (AI)-powered personal healthcare assistant. This filing

American Rebel Light Beer Connecticut Launch Party at Toad’s Place Presented by Dichello Distributors

Nashville, TN, Oct. 15, 2024 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), America’s Patriotic Brand and the creator of American Rebel Beer (www.americanrebelbeer.com), and branded safes, personal security and self-defense products and apparel, today announced American Rebel Beer’s Connecticut launch party at the legendary Toad’s Place in New

Wellspring Accelerates Growth Trajectory with Key C-Suite Appointments Following Sopheon Acquisition

Arvada, CO, USA, Oct. 15, 2024 (GLOBE NEWSWIRE) — Wellspring, the world’s leading provider of Tech Transfer, Intellectual Property Management, and Innovation Management software solutions, today announced significant leadership appointments following its recent acquisition of Sopheon, a major player in enterprise innovation management solutions. These strategic hires are set to enhance Wellspring’s position as a

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at ACG’s 2024 Annual Scientific Meeting being

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, provides an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee examined weekly administration

Concentrix Positioned as a Leader in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix(R) Assessment 2024

NEWARK, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, announced today that leading research firm Everest Group has positioned the company as a Leader in its Europe, Middle East and Africa (EMEA) Customer Experience Management (CXM) Services PEAK Matrix(R) Assessment 2024. For the third consecutive year,

Scroll to Top